Biomea Fusion completes enrollment in Phase II diabetes trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
August 24, 2026 7:00 AM EDTTopline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (T2D) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first quarter of 2027COVALENT-212 Phase II enrollment T2D patients who are not achieving glycemic targets despite GLP-1 based therapy is still ongoing, with topline 26-week primary endpoint data anticipated in the second quarter of 2027These ongoing Phase II diabetes trials target two distinct T2D populations that... More
